15q13.3 microdeletion syndrome causes a spectrum of cognitive disorders, including intellectual disability and autism. We aimed to determine if any or all of three cognitive testing systems (the KiTAP, CogState, and Stanford-Binet) are suitable for assessment of cognitive function in affected individuals. These three tests were administered to ten individuals with 15q13.3 microdeletion syndrome (14-18 years of age), and the results were analyzed to determine feasibility of use, potential for improvement, and internal consistency. It was determined that the KiTAP, CogState, and Stanford-Binet are valid tests of cognitive function in 15q13.3 microdeletion patients. Therefore, these tests may be considered for use as objective outcome measures in future clinical trials, assessing change in cognitive function over a period of pharmacological treatment.
Introduction
15q13.3 microdeletion syndrome (OMIM #612001) is caused by small deletions in the extremely unstable q13.2-q13.3 region of chromosome 15, and is implicated in multiple neurodevelopmental disorders (Tropeano et al. 2014; Lowther et al. 2014 ). This chromosomal region contains seven genes and is flanked by a breakpoint (BP) on each side. The BPs are marked by clusters of low copy repeat (LCR) elements, which are vulnerable to inversion and subsequent non-allelic homologous recombination (NAHR), resulting in deletion of the involved region (Gillentine and Schaaf 2015) . Most clinical cases of this syndrome present with microdeletions occurring between BP4 and BP5 (Tropeano et al. 2014) . About 80 % of patients with this syndrome have one or more neuropsychiatric diagnoses, with 57.5 % diagnosed with developmental disability/intellectual disability (ID), 10.9 % diagnosed with autism spectrum disorder, 15.9 % diagnosed with speech problems, and 6.5 % diagnosed with attention deficit hyperactivity disorder (ADHD) (Lowther et al. 2014) . The neuropsychiatric phenotypes of 15q13.3 microdeletion syndrome have been proposed to be caused by haploinsufficiency of CHRNA7, which is one of the seven genes in the region affected by the microdeletions (Gillentine and Schaaf 2015) .
CHRNA7 codes for the a7 subunits composing the a7 homopentameric nicotinic acetylcholine receptor (a7nAChR), which is expressed throughout the brain (Schaaf 2014) . Here, the receptors are involved in neuronal calcium signaling, which helps to mediate synaptic plasticity, learning, and memory (Gillentine and Schaaf 2015) . The heterozygous deletion of this gene, as present in 15q13.3 microdeletion cases, has been proposed to lead to a decreased number of functional receptors, causing altered calcium signaling and, consequently, deficits in cognitive function. Agonists of a7nAChR have been shown to improve cognitive function in patients with schizophrenia during phase 1 clinical trials (Freedman 2014) . However, the therapeutic potential of such treatments in individuals with 15q13.3 microdeletion syndrome has not been assessed to date.
As is true for other groups of individuals with ID, there is a lack of well-established, objective tests validated for assessment of cognitive function in 15q13.3 microdeletion patients. This makes it difficult to accurately track changes in cognitive function of these patients throughout life. In addition, the efficacy of potential treatments in respective clinical trials is assessed primarily through subjective questionnaires. This results in a large placebo effect, and likely contributes to the low number of approved treatments for individuals with ID (Sandler 2005) .
Here, we assess performance of three test systems for cognitive function in a cohort of 15q13.3 del patients, aiming to identify potential outcome measures for clinical trials to be considered in this patient population.
Methods

Participants
Ten study participants were recruited for this study. Individuals were recruited from our own patient registry, based on a known diagnosis of 15q13.3 microdeletion syndrome. That diagnosis had been made by clinical chromosome microarray analysis prior to this study. A total of 18 families were contacted, with affected individuals between 12 and 21 years of age. The first 10 individuals to respond were consented for enrollment under a research protocol approved by the Institutional Review Board. Clinical details for these individuals are listed in Table 1 .
Procedures
Components of three test systems were administered to each subject: KiTAP (test of attentional performance in younger children), CogState, and Stanford-Binet (5th edition). Both the KiTAP and CogState were administered by the principal investigator (C.S.). These tests contain multiple components the user can choose to administer based upon the cognitive function they wish to assess. Components administered to these subjects, and cognitive functions assessed by each, are detailed in Table 2 for the KiTAP and Table 3 For the KiTAP and CogState components (except as noted below), regarding the ''Feasibility'' assessment (Table 4) , individuals ''Able to Perform Test'' were determined to be those who were able to respond to the test stimuli adequately enough to generate a score for the test component indicated. The subjects determined to be unable to perform the test component got zero answers correct for that component. ''Basal Effect'' represents subjects that ''Ceiling Effect'' indicates the subjects that made no errors in response to stimuli on that test component. For the international shopping list task (ISLT) and ISLT delayed (same day and 24 h) components of the CogState, and all Stanford-Binet components, ''Able to Perform Test'' were determined to be those who attempted to respond to the questions presented, and ''Basal Effect'' represents subjects who generated the lowest possible score for that component.
For the ''Proof of Potential for Improvement'' assessment (Table 5) , mean percentile rankings for the KiTAP outcome measures were obtained through converting the Tscores calculated by the testing software to percentile rankings using Appendix B in the KiTAP users manual. The normed values for this calculation were from test scores generated by healthy 8-10 years olds. Mean percentile rankings for the CogState components were obtained by calculating Z-scores for each individual and outcome, using normed data obtained from a true agematched cohort. These Z-scores were then converted to percentile rankings using the table found on MedFriendly (''MedFriendly: Standard Score to Percentile Conversion,'' n.d.) Z scores were calculated using the formula below. (Table 6 ). The test used to calculate this value was dependent upon the outcome variable assessed for each test component. Cronbach's alpha calculation was used to determine internal consistency in outcome variables with response measured on a scale i.e. reaction time (RT). Kuder Richardson 20 calculation was used to determine internal consistency in outcome variables with dichotomous responses i.e. correct or incorrect response. Test components with a value at or above 0.70 are considered to have an acceptable level of internal consistency. All internal consistency calculations were performed by assessing response via the primary outcome variable for each component, as determined by the testing instructions for each test. If more than one primary outcome variable was listed for a component, the first variable listed was used for the calculation. (Table 6 ).
Discussion
This is the first description of validation of these three test systems, assessing various elements of cognition, including memory, and attention, in a cohort of individuals with 15q13.3 microdeletion syndrome. Both the KiTAP and CogState have been used to assess cognitive function in ADHD populations, but use of the CogState has never been verified for use in subjects with ASD or ID (Jucaite et al. 2014; Mollica et al. 2004; Yamashita et al. 2011; Rothmann et al. 2014; Hellwig-Brida et al. 2011; Kaufmann et al. 2010) . Assessment of feasibility for use of the KiTAP in a Fragile X syndrome (FXS) cohort has been previously investigated, and it was found that this test is a valid assessment of cognitive function in FXS patients (Knox have you seen this card before), the stimulus presented remains the face of a random playing card. This type of repetitive stimulus across multiple test components presents the challenge of not being able to hold the attention of test takers as well as the more engaging KiTAP. This is especially true for adolescent populations, or any populations having attention deficits. Considering that our population was composed mostly of teenagers (average age = 15.6 years), and ADHD is one of the known clinical manifestations of 15q13.3 deletion, we conclude that the CogState may not be as good an assessment of cognitive function as the KiTAP in that particular population. This is supported by the fact that the two components displaying a basal effect over 20 % both come from the CogState test. Additionally, the percentile rankings of the CogState components are much lower than either the KiTAP or the Stanford-Binet. Although some of the difference between the CogState and KiTAP mean percentile rankings can be explained by age differences in the sources of normed values (age matched vs. 8-10 years olds), it is unlikely that the 4-8 years difference between normed values and actual age of test subjects in the KiTAP has such a profound effect on difference in percentile ranking. If this were the case, we would expect to see much more similar percentile rankings between components of the CogState and Stanford-Binet, since percentile rankings for both were calculated from age-matched norms. The lack of variance in mean percentile ranking between components of the CogState when compared to variances between components of the other two tests reinforces the concept that monotony in the CogState stimuli may result in less efficient distinction of different cognitive domains when compared to the KiTAP and Stanford-Binet. A larger cohort of 15q13.3 deletion individuals, as well as a healthy, age-matched control cohort for all components of the CogState, and KiTAP tests would help determine if indeed one of these tests is superior to the other for measuring cognitive function in 15q13.3 deletion patients.
Individuals with 15q13.3 Deletion are Capable of Obtaining Valid Scores on Components of the KiTAP, CogState, and Stanford-Binet Cognitive Batteries
When validating cognitive tests in a population with cognitive abnormalities, it is important to ensure that the subjects have the ability to respond to the test stimulus adequately enough to generate a valid score. Inability to generate a score on a test component could be a result of unwillingness to participate, or physical or mental disabilities resulting in a lack of ability to respond to the test stimulus appropriately. Based on the observation that all subjects were able to perform all but one test component, we conclude that our cohort is capable of responding to the stimuli presented by each test. For the one CogState test component that only 8 of 10 subjects were able to perform, it is likely that the two non-responding subjects were simply not engaged with this particular test component as they were both able to respond to all other test components with similar stimuli. It is also essential to verify that there is not a large basal or 'floor' effect, as is often the case when such populations take tests created to assess cognitive function in the normal population. The presence of a basal effect indicates that some individuals in the cohort being studied are generating a score at or below the guessing rate. This could indicate that the individual did not understand the test component instructions, or that they were not fully engaged in taking the test during that component. Ultimately, a large basal effect for a test component indicates that component is not a good measure of cognitive function in that group of individuals, likely because the task requires a higher level of function than the average individual in the group is capable of. The overall percentage of basal effect across test components of all three tests is low, and indicates that most of these test components are at an appropriate level of difficulty for our cohort. The presence of some basal effect in our subject population is expected due to the wide range and severity of phenotypes in 15q13.3 deletion patients. There were two components of the CogState presenting with a basal effect higher than 20 %. It is possible that these components are testing cognitive function at a level unsuitable for many of these subjects. However, it would be ideal to test these components on a larger cohort to determine if these results hold true over a more inclusive population of 15q13.3 deletion patients. Verifying a low ceiling effect is important in order to ensure that the cohort being studied does not perform so well on the test components that there is no room to improve scores. It is important to note that ceiling effect is based off of correct answers, as mentioned in the ''Methods'' and ''Results'' section. Therefore, for those test components whose primary outcome measure does not depend on correct response (i.e. mean RT), a large ceiling effect holds no meaning. This is the case in our cohort for all test components with a ceiling effect over 10 % (Table 2) . Based on this, we can conclude that the test components assessed in this study are testing cognitive function at a level that challenges our cohort, and that improvement upon initial test scores is possible.
Ample Potential for Improvement in 15q13.3 Deletion Cohort
To assess potential for improvement of test scores upon increased cognitive function in our 15q13.3 deletion cohort, we calculated the average baseline percentile rankings for our cohort across test components for all outcome measures having available normed values. The Stanford-Binet has been thoroughly standardized, with norms available for age matched standardization of each subject's scores. This has been done to a lesser extent for the KiTAP and CogState. For the KiTAP, a complete set of norms is available for age groups 6-7 and 8-10. However, no norms for age groups older than that are available. In the case of the CogState, a complete set of norms for primary outcome measures is available for age groups 18 and older, but only incomplete norms exist for ages younger than 18. While other assessments of test validity can be performed, this makes it difficult to accurately determine the average percentile ranking of our 15q13.3 deletion cohort. Some argue that these percentile rankings are not valid in ID populations (Knox et al. 2012) . While this may be accurate in some cases, the main point of assessing these rankings in our case is to show that there is definite room for improvement in the scores generated on the respective test components in individuals with 15q13.3 microdeletion syndrome. Comparing the scores generated by our cohort to those generated by healthy controls, we show that this is indeed the case. Both for the CogState and the Stanford-Binet tests, all of the mean percentile rankings obtained by the 15q13.3 deletion cohort are below the 50th percentile. The CogState mean percentile rankings are especially low (*3rd percentile), while the Stanford-Binet rankings are more variable depending on the skill being measured (6th-38th percentile). This is to be expected since the Stanford-Binet was developed primarily to assess IQ and reasoning ability, while the CogState was developed to assess more interactive cognitive functions such as psychomotor speed and attention. For the KiTAP, most of the mean percentile rankings are still below average (\50th percentile). However, it is important to remember that these percentile rankings compare our cohort to a normal cohort aged 8-10. Since our subjects were 14-18 years old (true ages) at the time of testing, it is reasonable to expect that they will score higher when compared to 8-10 years olds than when compared to an agematched cohort. The fact that the large majority of primary outcomes show percentile scores below average leaves room for improvement, in particular when considering clinical trials of pharmacologic intervention. Although a change in IQ scores (as measured by the Stanford-Binet) may not be seen over the course of a treatment trial period, it is likely that an effective treatment could be identified by monitoring changes in cognitive functions with the more sensitive CogState and KiTAP tests.
Acceptable Levels of Internal Consistency Across Components of the KiTAP and CogState Cognitive Batteries
Internal consistency is a measure of intra-individual agreement between different items/questions testing the same general function. A value of 1 represents perfect internal consistency, and any value above 0.70 indicates that the test component has an acceptable level of internal consistency.
Cronbach's alpha is the statistical test most often used to determine internal consistency across a group of questions meant to measure the same function. However, this test was created to measure how consistently individuals answered questions with the response being measured on a scale. For several test components we wished to assess, the primary outcome measure is not measured on a scale, but rather dichotomous (number of correct responses or number of errors). For these cases, Kuder-Richardson Formula 20 was used.
Since each component of these tests is essentially asking the same question over and over again, we would expect to see an alpha value close to 1 for components which the subjects understood instructions well, and were able to respond similarly to each question/stimulus.
Internal consistency statistics were not performed on Stanford-Binet components due to the nature of scoring (not every child starts at the same place, therefore questions will be different between children).
Based on the internal consistency statistics presented in Table 6 , it appears that each evaluated test component in both the KiTAP and the CogState has acceptable internal consistency in our cohort, with all but two components achieving a score above 0.80. There is only one test component, ''sustained attention'' from the KiTAP, which is on the border of the acceptable range. This value rounds up to 0.7 from 0.69, and would potentially be higher upon evaluation of a larger group of subjects.
Conclusions
Based on the data presented, we conclude that the KiTAP, CogState, and the Stanford-Binet are valid measures of cognitive function in individuals with 15q13.3 microdeletion syndrome. Along with previous studies in individuals with FXS, the data presented herein provide encouragement that some cognitive tests established in healthy patients may be used to assess cognitive function in individuals with psycho-cognitive abnormalities stemming from a range of genetic or environmental causes. The 15q13.3 microdeletion syndrome has great potential for therapeutic intervention, with haploinsufficiency of CHRNA7 being considered a likely contributor to the overall phenotype, and promising alpha7 agonist drugs and positive allosteric modulators being developed (Schaaf 2014) . This pilot study provides important groundwork that will be useful for sample size calculations and consideration of quantifiable outcome measures to be considered in clinical trials for individuals with 15q13.3 microdeletion syndrome.
